Kowa has been granted a patent for a pharmaceutical composition containing pemafibrate, a salt, or a solvate thereof. The composition has excellent homogeneity and consists of 0.017 to 4.2 mass % of pemafibrate in terms of a free form with respect to the total mass of the composition. The patent claims a solid pharmaceutical dosage form composition comprising pemafibrate as the active component in the specified amount. GlobalData’s report on Kowa gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Kowa, Eye-tracking wearables was a key innovation area identified from patents. Kowa's grant share as of September 2023 was 31%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11759456B2) discloses a solid pharmaceutical dosage form composition comprising pemafibrate as the active component. Pemafibrate is present in the composition in an amount ranging from 0.017 to 4.2 mass % in terms of the free form of pemafibrate with respect to the total mass of the pharmaceutical composition.
The composition can be formulated into various dosage forms such as tablets, capsules, granules, powders, or pills. It includes pharmaceutically acceptable additives, which are selected from a group of compounds including cellulose ethers, starch species, povidone species, silicic acid compounds, polyhydric alcohols, alkyl sulfate ester salts, disaccharide species, and cellulose.
The cellulose ether species in the composition can be alkylcellulose, hydroxyalkylcellulose, alkyl(hydroxyalkyl)cellulose, carboxyalkylcellulose, cross-linked polymers of carboxyalkylcellulose, or salts thereof. Examples of specific cellulose ether species include methylcellulose, ethylcellulose, hydroxypropylcellulose, hypromellose, carmellose, carmellose potassium, carmellose calcium, carmellose sodium, and croscarmellose sodium.
The starch species in the composition can be starch, hydroxyalkyl ether of starch, carboxyalkyl ether of starch, or salts thereof. Examples of specific starch species include hydroxypropyl starch, carboxymethyl starch, and salts thereof.
Other additives in the composition include povidone species (such as povidone and crospovidone), silicic acid compounds (such as hydrous magnesium silicate, hydrated silicon dioxide, and light anhydrous silicic acid), polyhydric alcohols (such as macrogol, erythritol, xylitol, mannitol, sorbitol, maltitol, and lactitol), alkyl sulfate ester salts (such as lauryl sulfate ester salt, tetradecyl sulfate ester salt, hexadecyl sulfate ester salt, and octadecyl sulfate ester salt), disaccharide species (such as sucrose, lactose, maltose, trehalose, palatinose, sucralose, and solvates thereof), and cellulose.
Overall, this patent discloses a solid pharmaceutical composition containing pemafibrate as the active component, along with various pharmaceutically acceptable additives. The composition can be formulated into different dosage forms and offers flexibility in terms of the selection of additives, allowing for customization based on specific formulation requirements.